Kaposi sarcoma lesions - Causes, Treatment & When to See a Doctor

What is Kaposi sarcoma lesions?

Kaposi sarcoma (KS) is a cancer that originates from the cells lining the blood and lymphatic vessels (endothelial cells). The hallmark of KS is the development of lesions—often purple, red, or brown‑colored patches, nodules, or plaques—that can appear on the skin, mucous membranes, and, in advanced disease, internal organs. Although KS is relatively rare in the general population, it is strongly linked to infection with human herpesvirus‑8 (HHV‑8, also called Kaposi sarcoma‑associated herpesvirus) and to states of immune suppression.

These lesions are not merely cosmetic; they can bleed, become ulcerated, or signal deeper organ involvement. Early recognition and appropriate evaluation are crucial to prevent progression.

Sources: Mayo Clinic; Centers for Disease Control and Prevention (CDC); National Cancer Institute (NCI).

Common Causes

Kaposi sarcoma lesions are not caused by a single factor. Instead, they arise in the context of several underlying conditions that either introduce HHV‑8 or weaken the immune system. The most common associations include:

• 1. Human herpesvirus‑8 (HHV‑8) infection – The essential viral driver of KS.
• 2. Acquired Immunodeficiency Syndrome (AIDS) – KS is an AIDS‑defining illness.
• 3. Immunosuppressive therapy after organ transplantation (iatrogenic KS).
• 4. Chronic corticosteroid use for autoimmune diseases.
• 5. Other severe immunodeficiencies such as congenital immunodeficiency disorders.
• 6. Endemic (African) KS – Occurs in sub‑Saharan Africa independent of HIV.
• 7. Classic (Mediterranean) KS – Typically affects older men of Eastern European or Middle Eastern descent.
• 8. Co‑infection with other oncogenic viruses (e.g., Epstein‑Barr virus) that further compromise immunity.
• 9. Age‑related immune senescence – The risk rises slightly with advancing age even without obvious immunosuppression.
• 10. Genetic susceptibility – Certain HLA types may predispose to persistent HHV‑8 infection.

While HHV‑8 infection is necessary, most people with the virus never develop KS; the additional immunologic factors listed above tip the balance toward malignant transformation.

Associated Symptoms

Kaposi sarcoma lesions may be the first sign of disease, but they often coexist with other clinical features, especially when the disease spreads beyond the skin.

• Skin changes – Flat patches, raised nodules, or ulcerated plaques, frequently on the lower extremities, face, or oral mucosa.
• Lymphedema – Swelling of an extremity due to lymphatic blockage from tumor infiltration.
• Respiratory symptoms – Cough, shortness of breath, or hemoptysis if KS involves the lungs.
• Gastrointestinal complaints – Abdominal pain, nausea, vomiting, or occult bleeding when lesions affect the stomach or intestines.
• Neurologic signs – Headaches, seizures, or focal deficits from central nervous system (CNS) involvement, though rare.
• Systemic “B” symptoms – Unexplained weight loss, night sweats, or low‑grade fever, often related to HIV co‑infection.
• Bleeding or ulceration – Lesions that become painful or bleed easily.

When lesions appear suddenly, multiply rapidly, or are accompanied by any of these systemic findings, prompt medical evaluation is warranted.

When to See a Doctor

Because KS can progress from a skin‑only disease to a life‑threatening systemic cancer, you should seek medical care if you notice any of the following:

• New purple, red, or brown lesions that do not resolve within a few weeks.
• Rapid increase in the size or number of existing lesions.
• Lesions that become painful, ulcerated, or bleed spontaneously.
• Swelling (lymphedema) of an arm, leg, or face without an obvious cause.
• Persistent cough, shortness of breath, or coughing up blood.
• Unexplained abdominal pain, vomiting, or tar‑colored stools (possible GI bleeding).
• Neurologic symptoms such as headaches, vision changes, or weakness.
• Any new skin change in a person living with HIV/AIDS or who is on long‑term immunosuppressive medication.

Early detection improves treatment outcomes and may limit the need for aggressive systemic therapy.

Diagnosis

Diagnosing KS requires a combination of clinical examination, imaging, and tissue confirmation.

1. Clinical Evaluation

• Detailed medical history—including HIV status, transplant history, and medication use.
• Full skin examination, paying special attention to the legs, genital area, and oral cavity.

2. Skin Biopsy

The gold‑standard test. A small piece of the lesion is examined under a microscope. Classic histologic features include:

• Spindle‑shaped endothelial cells.
• Formation of new blood‑filled channels.
• Inflammatory infiltrate and hemosiderin deposits.

Immunohistochemical staining for HHV‑8 latent nuclear antigen (LANA‑1) confirms the viral association.

3. Laboratory Tests

• HIV viral load and CD4 count (if applicable).
• Complete blood count (CBC) and liver/kidney panels to assess baseline organ function before therapy.

4. Imaging Studies

• Chest X‑ray or CT scan – Detect pulmonary involvement.
• Abdominal CT or MRI – Evaluate gastrointestinal or visceral disease.
• Positron emission tomography (PET) – Useful for staging in advanced cases.

5. Endoscopic Evaluation

If GI symptoms are present, upper endoscopy or colonoscopy with biopsies may be performed to locate internal lesions.

6. Staging

KS is staged using the AIDS Clinical Trials Group (ACTG) system (T – tumor extent, I – immune status, S – systemic illness) for HIV‑related disease, or the WHO staging for classic/endemic forms.

Treatment Options

Treatment is individualized based on disease extent, immune status, and patient comorbidities. Goals are to control tumor growth, relieve symptoms, and improve survival.

1. Antiretroviral Therapy (ART)

For patients with HIV, initiating or optimizing ART is the most effective single measure. Viral suppression often leads to regression of KS lesions.

2. Local Therapies (skin‑limited disease)

• Intralesional chemotherapy – Vincristine or bleomycin injected directly into the lesion.
• Radiation therapy – Low‑dose external beam radiation for painful or rapidly growing nodules.
• Topical agents – Timolol gel (beta‑blocker) has shown anecdotal success for small superficial lesions.
• Cryotherapy – Liquid nitrogen freezing for isolated plaques.

3. Systemic Chemotherapy

Indicated when disease is widespread or involves internal organs.

• Liposomal doxorubicin – First‑line agent with a favorable side‑effect profile.
• Paclitaxel – Effective for refractory KS or in patients who cannot tolerate anthracyclines.
• Combination regimens – E.g., liposomal doxorubicin plus oral etoposide for aggressive disease.

4. Immunomodulatory Agents

• Interferon‑α – Used in classic KS with modest response; limited by flu‑like side effects.
• Immune checkpoint inhibitors (e.g., pembrolizumab) – Early case series suggest activity in refractory KS, but data are still emerging.

5. Surgical Management

Excision may be considered for solitary, well‑circumscribed lesions, especially on the face or genitals, to improve cosmetic outcome.

6. Supportive & Home Care

• Good skin hygiene; avoid trauma to lesions.
• Moisturizers to prevent cracking and secondary infection.
• Compression garments for lymphedema.
• Smoking cessation – reduces pulmonary complications.
• Nutrition counseling if gastrointestinal KS causes malabsorption.

Prevention Tips

Because HHV‑8 infection is common in certain regions, complete eradication is not feasible, but the following measures can lower the risk of developing KS lesions:

• Practice safe sex – Use condoms to reduce HHV‑8 transmission, especially with multiple partners.
• Get tested for HIV and start ART promptly if positive.
• Avoid unnecessary immunosuppression – Use the lowest effective dose of steroids or other immunosuppressants.
• Regular medical follow‑up for transplant recipients and patients on chronic immunosuppressive therapy.
• Vaccinations – Stay up‑to‑date with vaccines (e.g., hepatitis B, HPV) to prevent co‑infections that can further weaken immunity.
• Maintain a healthy lifestyle – Balanced diet, regular exercise, and adequate sleep support immune function.

Emergency Warning Signs

Key Take‑aways

Kaposi sarcoma lesions are a visible manifestation of a virus‑driven, immune‑related cancer. Early detection, especially in people living with HIV or on immunosuppressive drugs, can lead to effective treatment with antiretroviral therapy, local measures, or systemic chemotherapy. Maintaining immune health, practicing safe behaviors, and promptly reporting concerning changes are the best strategies to reduce morbidity and improve outcomes.

References:

1. Mayo Clinic. “Kaposi sarcoma.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/kaposi-sarcoma
2. CDC. “Kaposi Sarcoma – HIV/AIDS.” 2022. https://www.cdc.gov/hiv/basics/kaposi-sarcoma.html
3. National Cancer Institute. “Kaposi Sarcoma Treatment (PDQ®)–Patient Version.” 2024. https://www.cancer.gov/types/soft-tissue-sarcoma/patient/kaposi-sarcoma-treatment-pdq
4. World Health Organization. “Human herpesvirus 8 (HHV‑8) and Kaposi sarcoma.” 2023. https://www.who.int/news-room/fact-sheets/detail/human-herpesvirus-8
5. Cleveland Clinic. “Kaposi’s Sarcoma.” 2024. https://my.clevelandclinic.org/health/diseases/17074-kaposis-sarcoma